Sceptics may question the robustness of an early glimpse of mid-stage data for a well-worn neurodegenerative disease candidate but it is tough to doubt how real the upside has been for Annovis Bio.
Annovis Bio was issued a patent (US 10,383,851) in August 2019 for a method of treating Parkinson’s disease, Lewy body dementia and other Lewy body diseases in humans by administering its lead compound ...